PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
BUSINESS
Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
Daiichi Sankyo said on March 10 that its patent dispute with Seagen over its anti-HER2 antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has been concluded, with the Japanese company’s victory now finalized. The US Court of Appeals for the Federal…
To read the full story
Related Article
- Daiichi Sankyo Wins US Appeal in Seagen ADC Patent Dispute
December 4, 2025
- Daiichi Sankyo’s ADC Arbitration Win Finalized with No Appeal
July 1, 2024
- US Patent Office Nixes Seagen Patent in ADC Row: Daiichi Sankyo
January 18, 2024
- Daiichi Sankyo Wins ADC Patent Row against Seagen, Appeals Unfavorable Ruling in Enhertu Suit
November 21, 2023
- Daiichi Sankyo Ordered to Pay 8% Royalty to Seagen in ADC Patent Row
October 19, 2023
- US Patent Office Restarts PGR for Seagen Patent: Daiichi Sankyo
February 20, 2023
- US Arbitrator Rejects Seagen’s Claims against Daiichi Sankyo in ADC Feud
August 16, 2022
- Texas Court Favors Seagen in Enhertu Patent Row, Daiichi Sankyo Poised to Challenge Ruling
July 21, 2022
- Jury Finds Enhertu Infringes Seagen Patent, Awards US$41.8 Million in Damages
April 12, 2022
BUSINESS
- JB Banks on Sustained Aid to Double Plasma Processing Capacity
October 27, 2026
- Keytruda Tops Japan Drug Sales in April-September: Encise
October 27, 2026
- Japan Pharma Earnings Season Opens as Drug Price Cuts, Patent Cliffs Test Growth
October 27, 2026
- Takeda Opens New Kyoto Garden Area to Preserve Plants Used in Cultural Heritage
October 27, 2026
- Otsuka Ramps Up CVC Investments, Already Backs 2 Biotechs
October 27, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…